Abstract: This invention is directed generally to substituted pyridinone and pyrimidinone compounds that generally inhibit p38 kinase, TNF, and/or cyclooxyge?ase activity. Such substituted pyridinone and pyrimidinone compounds include compounds generally corresponding in structure to the following formula: wherein Z, n, R1, R2a, R2b, R2c, R2d, R2e, R3a, R3b, R3c, R3d, R4, R5, R6, R7a, R7b, R7c, R7d and R7e are as defined in this specification. This invention also is directed to compositions of such substituted pyridinones and pyrimidinones (particularly pharmaceutical compositions), and methods for treating disorders (typically pathological disorders) associated with p38 kinase activity, TNF activity, and/or cyclooxygenase-2 activity.

Abstract: An evaporator including a shell having a first end and a second end. A plurality of tubes are disposed within the shell to circulate refrigerant through the shell. A plurality of shell inlets are in fluid communication with the shell to deliver a fluid to exchange heat in the plurality of tubes, preferably through a baffle arrangement. At least one of the shell inlets may be arranged to deliver fluid to the shell adjacent to the first end. In addition, at least one of the other shell inlets may be arranged to deliver fluid adjacent to the second end. A shell outlet is in fluid communication with the shell to discharge fluid from the shell. The shell outlet is arranged to receive the combined liquid delivered to the shell by the plurality of shell inlets.

Abstract: An evaporator including a shell having a first end and a second end. A plurality of tubes are disposed within the shell to circulate refrigerant through the shell. A plurality of shell inlets are in fluid communication with the shell to deliver a fluid to exchange heat in the plurality of tubes, preferably through a baffle arrangement. At least one of the shell inlets may be arranged to deliver fluid to the shell adjacent to the first end. In addition, at least one of the other shell inlets may be arranged to deliver fluid adjacent to the second end. A shell outlet is in fluid communication with the shell to discharge fluid from the shell. The shell outlet is arranged to receive the combined liquid delivered to the shell by the plurality of shell inlets.

Abstract: Compounds of the formula (I): wherein R1, R2, R4 and R13 are as defined or a pharmaceutically or veterinarily acceptable salt or polymorph thereof, or a pharmaceutically or veterinarily acceptable solvate or pro-drug thereof: are potent and selective inhibitors of type 5 cyclic guanosine 3?,5?-monophosphate phosphodiesterase (cGMP PDE5) and have utility in the treatment of, inter alia, male erectile dysfunction (MED) and female sexual dysfunction (FSD).

Abstract: This invention relates to nicotinamide derivatives of general formula (I): in which R1, Z and R2 have the meanings defined herein, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of such derivatives.

Abstract: A compound of formula (I), or a pharmaceutically acceptable salt and/or solvate (including hydrate) thereof; and the use of a compound of formula (I) in the treatment of a TNF-mediated disease, disorder, or condition, or a p38-mediated disease, disorder, or condition, in particular the allergic and non-allergic airways diseases, more particularly obstructive or inflammatory airways diseases, preferably chronic obstructive pulmonary disease.

Abstract: The invention relates to nicotinamide derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The nicotinamide derivatives according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic, respiratory diseases, disorders and conditions, as well as wounds.

Abstract: The present invention relates to tetrahydronaphthyridine derivatives of the general formula (I): or of the general formula (I?) in which A and R1 are as defined within, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, including the treatment diseases mediated by H3 ligands, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

Abstract: This invention relates to nicotinamide derivatives of general formula (I): in which R1, Z and R2 have the meanings defined herein, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of such derivatives.

Abstract: This invention relates to nicotinamide derivatives of general formula (I): in which R1, R2 and R3 have the meanings defined herein, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of such derivatives.

Abstract: This invention relates to nicotinamide derivatives of general formula (I): in which R1, R2 and R3 have the meanings defined herein, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of such derivatives.

Abstract: This invention relates to nicotinamide derivatives of general formula (I): in which R1, R2 and R3 have the meanings defined herein, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of such derivatives.

Abstract: This invention relates to nicotinamide derivatives of general formula (I): in which R1, Z and R2 have the meanings defined herein, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of such derivatives.